Truist assumed coverage of Regeneron (REGN) with a Buy rating with a price target of $798, down from $812. The firm views Regeneron as a differentiated large-cap biopharma name, combining a durable commercial foundation with an innovation-led pipeline strategy, the analyst tells investors in a research note. Regeneron’s core franchises such as Eylea, Dupixent, and Libtayo provide stability, while its strong balance sheet and proprietary technology platform underpins the company’s long-term growth optionality, the firm added.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN: